BDSX
Biodesix Inc
$21.42
-0.73 (-3.30%)
At close · Jul 10
Market Cap
$232.50M
Shares
10,108,580
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$21.42
Open$22.00
Day$21.17–23.32
52W$5.26–24.92
Avg vol 30d85K
Short int105K · 1.0% float · 1.0d
Short vol52%
Last earningsMay 4, 2026
DataOct 2020–Jul 2026
Filing10-Q · May 4
Up next
Next earnings call
Jul 30, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 4, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+83%
above
Price vs 50-day avg
+29%
above
RSI (14)
58
neutral
MACD trend
Negative
52-week position
82%
mid-range
Momentum
relative strength
1-month return
+43%
trailing
6-month return
+157%
trailing
YTD return
+215%
this year
Relative strength
+148%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+54% holders QoQ · +24 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.04% of float · ▲ +0.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
40 holders — 13F breadth
Squeeze score
41
elevated · 0–100
Fundamentals
Revenue growth
+24%
Y/Y
EPS growth
+30%
Y/Y
Free cash flow
$-23.5M
Balance sheet
$31.0M
net debt
Quant / Vol
risk profile
Volatility
116%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
9.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 4, 2026
Total Revenue
· full year 2026
Maintained
$108M – $114M
prior FY $88.5M
midpoint +25.4% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+83%
Bullish
Price vs 50-day avg
+29%
Bullish
RSI (14)
58
Neutral
MACD trend
Negative
Bearish
52-week position
82%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $17 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+54% holders QoQ · +24 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.04% of float · ▲ +0.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
40 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $5
Now $21 · 82%
52-wk high $25
vs 200-day avg +83%
vs 50-day avg +29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$4.1M | Q1 2026 | — |
|
|
|||
| Test volumes | 17,800 | Q1 2026 | — |
| average sales representatives in the field | 100 | first quarter call | — |
| contracted development services backlog | $10.4M | first quarter call | — |
| Diagnostic Test test volumes | 62,600 | FY2025 | — |
| Diagnostic Tests core organic revenue, excluding collection on claims older than one year | $24.1M | Q4 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BDSX
this stock
Biodesix Inc
|
$232.50M | +215.0% | +45.3% | — | 1.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$195.86B | -9.0% | +0.4% | 29.0 | 1.4% |
|
DHR
Danaher Corp /De/
|
$138.71B | -12.7% | +8.5% | 37.8 | 1.5% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.46B | -16.7% | +10.4% | 41.5 | 2.5% |
|
NTRA
Natera, Inc.
|
$38.66B | +17.8% | -2.8% | — | 4.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BDSX | -2.6% | +42.7% | +157.1% | -5.0% | +215.0% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -4.0% | +38.6% | +148.1% | -6.1% | +204.3% |